🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/11/2013 37,71 39,04 37,37 38,25 +0,84% 4,43% 832.000
04/11/2013 38,36 39,46 37,30 37,93 +1,09% 5,63% 1.411.900
01/11/2013 38,76 39,00 36,85 37,52 -3,60% 5,55% 1.672.100
31/10/2013 38,91 40,12 38,25 38,92 +0,75% 4,81% 1.184.000
30/10/2013 40,75 41,66 38,04 38,63 -7,78% 8,88% 2.861.600
29/10/2013 42,27 42,70 40,86 41,89 -1,06% 4,35% 1.774.300
28/10/2013 42,76 43,44 41,50 42,34 -1,03% 4,54% 843.300
25/10/2013 43,31 44,03 42,42 42,78 -0,88% 3,72% 804.100
24/10/2013 42,40 44,29 42,35 43,16 +2,06% 4,58% 1.285.900
23/10/2013 41,57 42,80 40,13 42,29 +1,56% 6,42% 1.780.700
22/10/2013 41,49 42,54 39,83 41,64 +0,36% 6,53% 1.550.200
21/10/2013 42,98 43,71 41,32 41,49 -3,56% 5,56% 1.958.400
18/10/2013 46,07 46,27 42,42 43,02 -6,58% 8,36% 2.720.100
17/10/2013 47,53 47,60 45,34 46,05 -2,48% 4,75% 1.428.800
16/10/2013 45,44 48,32 45,40 47,22 +4,63% 6,43% 1.280.600
15/10/2013 45,11 46,60 44,76 45,13 +0,02% 4,08% 1.222.400
14/10/2013 46,00 46,23 44,43 45,12 -3,28% 3,91% 1.942.100
11/10/2013 47,19 48,72 46,07 46,65 -1,12% 5,62% 1.743.400
10/10/2013 45,61 48,39 44,56 47,18 +6,21% 8,40% 2.888.700
09/10/2013 49,86 50,31 43,60 44,42 -11,25% 13,46% 4.671.900
08/10/2013 54,60 55,48 49,40 50,05 -6,99% 11,14% 2.907.600
07/10/2013 52,72 55,61 52,28 53,81 +0,62% 6,32% 2.688.900
04/10/2013 50,79 54,42 50,71 53,48 +5,52% 7,30% 3.290.500
03/10/2013 48,61 52,20 48,32 50,68 +5,52% 7,98% 3.251.800
02/10/2013 47,17 48,46 46,64 48,03 +1,07% 3,86% 1.244.600
01/10/2013 47,34 47,76 46,87 47,52 +0,61% 1,88% 1.213.900
30/09/2013 46,14 48,26 45,73 47,23 +0,94% 5,48% 1.262.300
27/09/2013 46,50 47,75 46,25 46,79 +0,58% 3,23% 899.000
26/09/2013 44,95 47,67 43,64 46,52 +0,17% 8,97% 2.697.600
25/09/2013 47,50 49,61 46,05 46,44 -2,46% 7,49% 2.332.600